Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)
OpenUpdated: Oct 30, 2025
Summary
The grant aims to support research on how HIV-induced immunometabolic changes in individuals on combination antiretroviral therapy affect immune responses and increase the risk of poor outcomes from secondary infections like Mycobacterium tuberculosis and Hepatitis B Virus. Eligible applicants include small businesses, various government entities, nonprofits, and educational institutions, among others. Application details are not specified in the provided text; for more information, applicants should refer to the full opportunity announcement or contact NIH Grants Information.
Full Description
Description
Eligibility
Eligible applicants
Business
- Small businesses
- For-profit organizations other than small businesses
Government
- State governments
- Federally recognized Native American tribal governments
- Special district governments
- County governments
- City or township governments
- Public and Indian housing authorities
Nonprofit
- Nonprofits non-higher education with 501(c)(3)
- Other Native American tribal organizations
- Nonprofits non-higher education without 501(c)(3)
Education
- Public and state institutions of higher education
- Private institutions of higher education
- Independent school districts
Miscellaneous
- Other
Additional information
Grantor contact information
Description
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Recommended Resource
Grant Writing Services on Fiverr
Top PickStruggling with grant applications? Get expert help from professional freelance writers on Fiverr — from research and proposal drafts to compliance review and submission. Secure funding faster with proven talent.